New combo therapy targets rare, aggressive kidney tumors
NCT ID NCT06302569
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two drugs—pembrolizumab (Keytruda) and enfortumab vedotin (Padcev)—in people with rare kidney cancers called collecting duct carcinoma and renal medullary carcinoma. About 23 patients with advanced or metastatic disease will receive the combination for three cycles, then continue pembrolizumab alone. The study aims to see how many patients respond, how long they live without the cancer growing, and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and Enfortumab Vedotin (Padcev)
What this could lead to
If successful, this could provide a new treatment option for people with rare, aggressive kidney cancers that are hard to treat.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL MEDULLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fondazione Irccs Istituto Dei Tumori Di Milano
RECRUITINGMilan, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••